🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Immune Mechanisms and ECMO Strategies for Moderate-to-Severe ARDS

Recruitingn/aAges 18 Years - anyAllSoutheast University, China
NCT07726940 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acute respiratory distress syndrome (ARDS) poses a major threat to human health. Despite extracorporeal membrane oxygenation (ECMO) support, mortality among patients with ARDS remains high due to severe complications and suboptimal mechanical ventilation strategies. Elucidating the mechanisms underlying ECMO-related complications and lung injury repair, and establishing a precision intervention pathway covering the entire course of ECMO management, are urgent unmet needs for improving outcomes in ARDS patients and addressing major public health challenges. This project focuses on five key scientific questions: 1. How can moderate-to-severe ARDS be classified into distinct clinical-immune phenotypes, and what are the optimal therapeutic targets for each phenotype? 2. What are the molecular mechanisms underlying severe complications in ARDS patients receiving ECMO support? 3. Which key i

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 1.Age ≥ 18 years 2.Meet the global new definition of moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). Exclusion Criteria: \- 1.Patients with a prior tracheostomy. 2.Patients who have received a lung transplant or initiated VV-ECMO support as a bridge to lung transplantation. 3.Patients with comorbid cardiogenic shock requiring VA-ECMO or VAV-ECMO support.
💊

What it tests

  • Not listed
📍

Where

39 sites
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
Fujian Provincial Hospital
Fuzhou, China
Zhongda Hospital, Southeast University
Nanjing, China
Qilu Hospital of Shandong University
Jinan, China
Sichuan Provincial People's Hospital
Chengdu, China
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
The Second Hospital of Jilin University
Changchun, China
The First People's Hospital of Chenzhou
Chenzhou, China

…and 31 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy